Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGb 761 for cognitive impairment in post-COVID-19 syndrome
2024-517199-39-00Phase 2Completed
- Sponsor
- Schwabe Group
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, triple-blind trial in post-COVID syndrome comparing EGb 761 active treatment with Placebo (2 arms). Primary endpoints: Neurocognitive test changes, Anxiety and depression scales and 3 more. Started Jan 2025; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-517199-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517199-39-00.